OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
STAT3, a Master Regulator of Anti-Tumor Immune Response
Cédric Rébé, François Ghiringhelli
Cancers (2019) Vol. 11, Iss. 9, pp. 1280-1280
Open Access | Times Cited: 100
Cédric Rébé, François Ghiringhelli
Cancers (2019) Vol. 11, Iss. 9, pp. 1280-1280
Open Access | Times Cited: 100
Showing 1-25 of 100 citing articles:
IL-6 in inflammation, autoimmunity and cancer
Toshio Hirano
International Immunology (2020) Vol. 33, Iss. 3, pp. 127-148
Open Access | Times Cited: 900
Toshio Hirano
International Immunology (2020) Vol. 33, Iss. 3, pp. 127-148
Open Access | Times Cited: 900
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou, Qiyu Tong, Bowen Liu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 726
Sailan Zou, Qiyu Tong, Bowen Liu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 726
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 323-339
Open Access | Times Cited: 227
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 323-339
Open Access | Times Cited: 227
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
Darleny Y. Lizardo, Chaoyuan Kuang, Suisui Hao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188447-188447
Open Access | Times Cited: 156
Darleny Y. Lizardo, Chaoyuan Kuang, Suisui Hao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188447-188447
Open Access | Times Cited: 156
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 716-729
Open Access | Times Cited: 30
Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, et al.
Nature Medicine (2024) Vol. 30, Iss. 3, pp. 716-729
Open Access | Times Cited: 30
Microalgae with Immunomodulatory Activities
Gennaro Riccio, Chiara Lauritano
Marine Drugs (2019) Vol. 18, Iss. 1, pp. 2-2
Open Access | Times Cited: 139
Gennaro Riccio, Chiara Lauritano
Marine Drugs (2019) Vol. 18, Iss. 1, pp. 2-2
Open Access | Times Cited: 139
The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy
Manoj Garg, Muthu K. Shanmugam, Vipul Bhardwaj, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 3, pp. 1291-1336
Closed Access | Times Cited: 119
Manoj Garg, Muthu K. Shanmugam, Vipul Bhardwaj, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 3, pp. 1291-1336
Closed Access | Times Cited: 119
Novel activators and small-molecule inhibitors of STAT3 in cancer
Lehe Yang, Shichong Lin, Lingyuan Xu, et al.
Cytokine & Growth Factor Reviews (2019) Vol. 49, pp. 10-22
Open Access | Times Cited: 111
Lehe Yang, Shichong Lin, Lingyuan Xu, et al.
Cytokine & Growth Factor Reviews (2019) Vol. 49, pp. 10-22
Open Access | Times Cited: 111
Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment
Christina Piperi, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
Cells (2019) Vol. 8, Iss. 11, pp. 1398-1398
Open Access | Times Cited: 94
Christina Piperi, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
Cells (2019) Vol. 8, Iss. 11, pp. 1398-1398
Open Access | Times Cited: 94
Targeting STAT3 Signaling Pathway in Colorectal Cancer
Antonios N. Gargalionis, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
Biomedicines (2021) Vol. 9, Iss. 8, pp. 1016-1016
Open Access | Times Cited: 69
Antonios N. Gargalionis, Kostas A. Papavassiliou, Athanasios G. Papavassiliou
Biomedicines (2021) Vol. 9, Iss. 8, pp. 1016-1016
Open Access | Times Cited: 69
Breast cancer tumor microenvironment affects Treg/IL-17-producing Treg/Th17 cell axis: Molecular and therapeutic perspectives
Farhad Seif, Zahra Torki, Hamidreza Zalpoor, et al.
Molecular Therapy — Oncolytics (2023) Vol. 28, pp. 132-157
Open Access | Times Cited: 29
Farhad Seif, Zahra Torki, Hamidreza Zalpoor, et al.
Molecular Therapy — Oncolytics (2023) Vol. 28, pp. 132-157
Open Access | Times Cited: 29
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation
Shuai Lu, Xibo Sun, Zhongbao Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 27
Shuai Lu, Xibo Sun, Zhongbao Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 27
Hypoxia-driven protease legumain promotes immunosuppression in glioblastoma
Lizhi Pang, Songlin Guo, Fatima Khan, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101238-101238
Open Access | Times Cited: 25
Lizhi Pang, Songlin Guo, Fatima Khan, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101238-101238
Open Access | Times Cited: 25
Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition
Sunanda Singh, Héctor W. Gómez, Shreya Thakkar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4722-4722
Open Access | Times Cited: 23
Sunanda Singh, Héctor W. Gómez, Shreya Thakkar, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4722-4722
Open Access | Times Cited: 23
Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice
Shima Bastaki, A. Surendar, Nasrin Ahmadpour Saheb, et al.
Life Sciences (2020) Vol. 266, pp. 118847-118847
Closed Access | Times Cited: 66
Shima Bastaki, A. Surendar, Nasrin Ahmadpour Saheb, et al.
Life Sciences (2020) Vol. 266, pp. 118847-118847
Closed Access | Times Cited: 66
Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival
Shukui Qin, Qing Li, Jian Xu, et al.
Cancer Science (2020) Vol. 111, Iss. 11, pp. 4218-4231
Open Access | Times Cited: 58
Shukui Qin, Qing Li, Jian Xu, et al.
Cancer Science (2020) Vol. 111, Iss. 11, pp. 4218-4231
Open Access | Times Cited: 58
Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities
Sagun Parakh, Matthias Ernst, Ashleigh R. Poh
Cancers (2021) Vol. 13, Iss. 24, pp. 6228-6228
Open Access | Times Cited: 46
Sagun Parakh, Matthias Ernst, Ashleigh R. Poh
Cancers (2021) Vol. 13, Iss. 24, pp. 6228-6228
Open Access | Times Cited: 46
STAT3/miR-135b/NF-κB axis confers aggressiveness and unfavorable prognosis in non-small-cell lung cancer
Jinlin Zhao, Xin Wang, Zeyun Mi, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 5
Open Access | Times Cited: 45
Jinlin Zhao, Xin Wang, Zeyun Mi, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 5
Open Access | Times Cited: 45
Inhibiting STAT3 signaling pathway by natural products for cancer prevention and therapy: In vitro and in vivo activity and mechanisms of action
Jing Yang, Lingling Wang, Xiaoqing Guan, et al.
Pharmacological Research (2022) Vol. 182, pp. 106357-106357
Closed Access | Times Cited: 36
Jing Yang, Lingling Wang, Xiaoqing Guan, et al.
Pharmacological Research (2022) Vol. 182, pp. 106357-106357
Closed Access | Times Cited: 36
The complex network of transcription factors, immune checkpoint inhibitors and stemness features in colorectal cancer: A recent update
Maysaloun Merhi, Fareed Ahmad, Nassiba Taib, et al.
Seminars in Cancer Biology (2023) Vol. 89, pp. 1-17
Open Access | Times Cited: 22
Maysaloun Merhi, Fareed Ahmad, Nassiba Taib, et al.
Seminars in Cancer Biology (2023) Vol. 89, pp. 1-17
Open Access | Times Cited: 22
Targeting the STAT3 oncogenic pathway: Cancer immunotherapy and drug repurposing
Yushan Dong, Jingyu Chen, Yuhan Chen, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115513-115513
Open Access | Times Cited: 21
Yushan Dong, Jingyu Chen, Yuhan Chen, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 167, pp. 115513-115513
Open Access | Times Cited: 21
Inflammatory Networks in Renal Cell Carcinoma
Linus Kruk, Medina Mamtimin, Attila Braun, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2212-2212
Open Access | Times Cited: 19
Linus Kruk, Medina Mamtimin, Attila Braun, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2212-2212
Open Access | Times Cited: 19
STAT3 blockade ameliorates LPS-induced kidney injury through macrophage-driven inflammation
Song Hee Lee, Kyu Hong Kim, Seong Min Lee, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
Song Hee Lee, Kyu Hong Kim, Seong Min Lee, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 8
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
Shanthi Ganesh, Min Ju Kim, Jenny Lee, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 1895-1916
Open Access | Times Cited: 7
Shanthi Ganesh, Min Ju Kim, Jenny Lee, et al.
Molecular Therapy (2024) Vol. 32, Iss. 6, pp. 1895-1916
Open Access | Times Cited: 7
Coagulation Protease-Driven Cancer Immune Evasion: Potential Targets for Cancer Immunotherapy
Subhojit Paul, Tanmoy Mukherjee, Kaushik Das
Cancers (2024) Vol. 16, Iss. 8, pp. 1568-1568
Open Access | Times Cited: 7
Subhojit Paul, Tanmoy Mukherjee, Kaushik Das
Cancers (2024) Vol. 16, Iss. 8, pp. 1568-1568
Open Access | Times Cited: 7
